Clinical Trial Detail

NCT ID NCT01292655
Title Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Bristol-Myers Squibb
Indications

non-small cell lung carcinoma

melanoma

pancreatic cancer

Her2-receptor negative breast cancer

ovarian cancer

Advanced Solid Tumor

Therapies

BMS-906024

Age Groups: adult

Additional content available in CKB BOOST